European RTD programmes and global benefits 6CP Workshop, Helsinki June 2004 Pirjo Kutinlahti & Marjo Uotila

VTT Technology Studies Content General dynamics of EU Framework Programme Case I: Finnish shipbuilding industry and developing environmentally sustainable ships Case II: Medical research collaboration and developing vaccines for AIDS Conclusions

VTT Technology Studies General dynamics of EU FPs Increased European competitiveness and networking between companies and research organisations Adoption of societal objectives since the mid-1990s Precompetitive approach long-term perspective; commercial benefits are expected in the future advanced generic technologies (biotechnology, materials science, information technology and telecommunications) Increasing collaboration with non-EU countries

VTT Technology Studies Questions to be discussed Can the EU Framework Programme promote both the industrial competitiveness and solve societal problems? What kind of potential positive impacts may the EU Framework Programme have on the quality of life and environment? Is a win-win situation possible?

VTT Technology Studies Case I: Finnish shipbuilding industry and networking in marine research Fierce global competition Strategic alliances at national and European level Networking among suppliers, manufacturers, research organisations A new concept of shipbuilding: high investment in R&D specialisation cost-efficiency ship safety environmental protection life cycle model: manufacturing and services

VTT Technology Studies Expected benefits of networking in maritime research Economic benefits: Reduced costs of manufacturing Less energy-consuming ships Financial security for small companies and potential growth of the company Societal benefits: Limited consequences of accidents Less environmental pollution Slowing climate change

VTT Technology Studies CASE II: Networking in medical research and vaccine development Facts about the AIDS Currently 40 million hiv positive 95% of whom live in developing countries 3 million of whom are children new hiv infections each day 0,1% of the hiv infected people in the Southern Africa receive any medical treatment 40 million AIDS orphans by the year 2010 Development of AIDS vaccines Hindrances: Scientific challenge Low company interests in developing vaccines Low political will EU FP initiatives to promote HIV/AIDS research Finnish scientists active in the EU FPs

VTT Technology Studies Expected benefits of networking in medical research Benefits for scientists and academic research: Increased scientific prestige for academics and improved quality of research Benefits for European companies: Reduced risk on R&D Improved know-how and expertise Nation-wide benefits: Savings in healthcare Improved quality of life Longer life expectancy

VTT Technology Studies Conclusions Increased awareness of societal demands among scientists and companies Intertwined economic, academic and societal approach as a rationale for public support on R&D Responding to global societal demands at European level